ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.56
+0.30 (3.63%)
At close: May 1, 2026, 4:00 PM EDT
8.50
-0.06 (-0.70%)
After-hours: May 1, 2026, 7:08 PM EDT
ARS Pharmaceuticals Revenue
In the year 2025, ARS Pharmaceuticals had annual revenue of $84.28M, down -5.46%. ARS Pharmaceuticals had revenue of $28.09M in the quarter ending December 31, 2025, a decrease of -67.56%.
Revenue (ttm)
$84.28M
Revenue Growth
-5.46%
P/S Ratio
10.09
Revenue / Employee
$517,043
Employees
163
Market Cap
849.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.28M | -4.87M | -5.46% |
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Theravance Biopharma | 107.46M |
| MeiraGTx Holdings | 81.39M |
| Arbutus Biopharma | 14.08M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
SPRY News
- 18 days ago - neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - GlobeNewsWire
- 7 weeks ago - ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - ARS Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 3 months ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire